聚克隆抗体治疗的最新发展和未来临床前景
Patrick Wightman1, William Kelton1,2
1School of Pharmacy and Biomedical Science, University of Waikato, Hamilton, New Zealand.
Expert opinion on biological therapy
|December 19, 2025
概括
多克隆抗体 (pAbs) 正在重新引起人们的兴趣,因为它们的多位向,挑战单克隆抗体 (mAbs). 新兴的重组pAb技术提供了潜在的好处,但面临着成本效益的不确定性.
科学领域:
- 免疫学和治疗学 免疫学和治疗学
- 生物技术是生物技术.
背景情况:
- 自2000年代初以来,单克隆抗体 (mAbs) 已经主导了抗体疗法.
- 多克隆抗体 (pAbs) 由于其多皮托普向能力而重新引起人们的兴趣.
- 复合抗体池等新兴技术正在重塑mAb和pAb疗法之间的区别.
研究的目的:
- 探索FDA批准的多克隆抗体疗法的当前应用.
- 评估单克隆抗体替代多克隆抗体疗法的潜力.
- 讨论竞争的mAb和pAb疗法的成本效益,并审查新兴的pAb技术.
主要方法:
- 基于FDA批准的多克隆疗法进行文献搜索.
- 对临床应用,成本效益和新兴技术 (糖人化和重组pAbs) 的分析.
主要成果:
- 多克隆抗体疗法领域充满活力,并面临着不断发展的单克隆抗体的竞争.
- 多种mAb替代品正在临床开发中,用于目前pAbs.治疗的适应症.
- 新兴的重组pAbs可能会提供更好的安全性和一致性,但成本效益不确定.
结论:
- 多克隆抗体 (pAbs) 提供独特的多皮托普向优势.
- 单克隆抗体 (mAbs) 与当前的pAb疗法存在明显的竞争.
- 未来的pAb创新,如重组方法是有前途的,但需要进一步评估成本效益.
相关概念视频
Hybridoma Technology
17.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.1K
Preclinical Development: Overview
5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Microorganisms in Medicine and Therapeutics
914
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
914
Antibody Actions
2.3K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
2.3K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cross-reactivity
32.8K
Overview
32.8K


